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IFI16 is amember of the interferon-inducible HIN-200
family of nuclear proteins. It has been implicated in
transcriptional regulation by modulating protein-
protein interactions with p53 tumor suppressor
protein and other transcription factors. However,
the mechanisms of interaction remain unknown.
Here, we report the crystal structures of both HIN-A
and HIN-B domains of IFI16 determined at 2.0 and
2.35 A˚ resolution, respectively. Each HIN domain
comprises a pair of tightly packed OB-fold subdo-
mains that appear to act as a single unit. We show
that both HIN domains of IFI16 are capable of
enhancing p53-DNA complex formation and tran-
scriptional activation via distinctive means. HIN-A
domain binds to the basic C terminus of p53,
whereas the HIN-B domain binds to the core DNA-
binding region of p53. Both interactions are compat-
ible with the DNA-bound state of p53 and together
contribute to the effect of full-length IFI16 on p53-
DNA complex formation and transcriptional activa-
tion.
INTRODUCTION
Interferons (IFNs) are cytokines involved in diverse biological
functions including regulation of antiviral, antibacterial, immune,
and inflammatory responses (Gutterman, 1994; Stark et al.,
1998). The effects of IFN stimulation are often manifested
through activation of IFN-inducible genes. Although many genes
are known to be activated by this pathway, their biological and
functional importance remains unclear.
The IFN-inducible HIN-200 gene family encodes a class of
homologous proteins that share a 200-amino acid signature
motif (HIN) (Dawson and Trapani, 1996). Four human (IFI16,
MNDA, AIM2, and IFIX) and five mouse (p202a, p202b, p203,
p204, and p205) members of this family have been identified418 Structure 19, 418–429, March 9, 2011 ª2011 Elsevier Ltd All righ(Figure 1A). Most of the HIN-200 proteins possess two major
protein domains. At the N terminus, there is a conserved
a-helical PYRIN domain, which belongs to the death domain-
containing protein superfamily involved in apoptosis, inflamma-
tion, and immune responses (Hiller et al., 2003; Stehlik and
Reed, 2004). At the C terminus, all HIN-200 proteins possess
either one or two copies of a conserved HIN domain, which
has been implicated in DNA binding, as well as in mediating
protein-protein interactions for transcriptional regulation (Koul
et al., 1998; Xin et al., 2003; Ludlow et al., 2005; Yan et al., 2008).
The mouse protein p202a, containing two HIN domains exclu-
sively, is the most studied member of the HIN-200 family. The
HIN repeats in p202a have been shown to interact with
numerous transcription factors including pRB, p53, NFkB,
AP-1, MyoD, and E2F, indicating that the HIN domain may serve
as a scaffold to assemble large protein complexes to modulate
the transcription of target genes (Choubey, 2000; Xin et al.,
2003). The human HIN-200 homolog IFI16, whose primary
sequence predicts a PYRIN domain and two tandem HIN
domains, has also been implicated in binding to pRB, E2F1,
p53, and BRCA1 (Johnstone et al., 2000; Aglipay et al., 2003;
Xin et al., 2003). Recently, human AIM2 was shown to be essen-
tial for sensing cytoplasmic foreign DNA through its HIN domain
and interacting with an apoptosis-associated protein, ASC, via
its PYRIN domain, leading to activation of inflammatory
responses (Fernandes-Alnemri et al., 2009; Hornung et al.,
2009; Roberts et al., 2009).
The observation that these HIN-200 proteins interact with
several cellular regulators involved in cell cycle control, prolifer-
ation, differentiation, and apoptosis hints that the physiological
role of HIN-200 proteins may lie beyond the IFN system (Ludlow
et al., 2005; Ding et al., 2006). Indeed, IFI16 is widely expressed
in normal human endothelial and epithelial cells in addition to
hematopoietic cells (Gariglio et al., 2002; Wei et al., 2003;
Raffaella et al., 2004; Ludlow et al., 2005). Several studies have
demonstrated that loss or reduced expression of IFI16 is often
associated with various forms of human cancers, including those
of the pancreas, prostate, and breast (Trapani et al., 1992; Xin
et al., 2003; Fujiuchi et al., 2004); leading to the notion that
IFI16 may play an important role in tumor suppression. However,
the molecular mechanism by which IFI16 exerts its activityts reserved
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Figure 1. The HIN Domains of IFI16
(A) Overall domain architecture of the HIN-200 proteins in human (IFI16, MNDA, AIM2, IFIX) andmouse (p202a/b, p203, p204, p205). The PYRIN and HIN domains
are indicated by the cyan and yellow shadings, respectively. Red shadings highlight S/T- rich region.
(B) Structure of HIN-A (left) or HIN-B (right) domain of IFI16 in cartoon representation. N and C termini are indicated.
See also Figure S1.
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IFI16 Interaction with p53remains unknown. Understanding the IFI16-mediated protein-
protein interaction will provide insight into its mechanism of
action and function.
Inactivation of the p53 tumor suppressor gene occurs in more
than half of human cancers, and loss of p53 function is a fun-
damental step in the pathogenesis of most human cancers
(Vogelstein and Kinzler, 1992). The p53 protein functions as
a transcription factor and can transactivate cellular genes
through sequence-specific DNA binding to their promoters
(Prives and Manley, 2001). Although the physiological signifi-
cance of IFI16 in p53 biology is still under investigation, it has
been reported to regulate p53-mediated transcriptional activa-
tion (Johnstone et al., 2000; Fujiuchi et al., 2004; Xin et al.,
2004). In addition, IFI16 also plays a role in p53-mediated trans-
mission of apoptosis signaling in response to DNA damage, byStructure 19,upregulating p53 and downregulating MDM2 (Fujiuchi et al.,
2004). Furthermore, tetracycline-regulated IFI16 also induced
apoptosis in the presence of ionizing radiation when coex-
pressed with p53 in human bladder carcinoma p53-deficient
EJ cells (Fujiuchi et al., 2004). Together, these studies suggest
that IFI16 is involved in the regulation of p53 stability, p53-
mediated transcriptional activation, and apoptosis.
In order to better understand the molecular details and mech-
anism of p53 regulation by IFI16, here, we present the crystal
structures of the HIN-A and HIN-B domains of IFI16 determined
at 2.0 and 2.35 A˚ resolution, respectively. These structures
represent the first experimentally determined HIN domain struc-
tures reported in the HIN-200 protein family. Although they are
structurally similar, HIN-A recognizes the C terminus of p53,
whereas HIN-B binds to the DNA-binding region of p53,418–429, March 9, 2011 ª2011 Elsevier Ltd All rights reserved 419
Table 1. Summary of Data Collection and Refinement Statistics
HIN-A (Se-SAD) HIN-B (Native)
Data Collection
Space group P21 P212121
Unit cell parameters
a, b, c (A˚) 43.3, 88.9, 112.8 43.0, 92.9, 100.3
a, b, g () 90.0, 99.4, 90.0 90.0, 90.0, 90.0
Wavelength l (A˚) 0.97918 1.0
Rmerge (%) 7.2 (38.9) 6.6 (37.9)
I/s(I) 31.4 (2.7) 26.4 (4.8)
Completeness (%) 96.4 (85.7) 99.9 (100)
Redundancy 4.1 (3.6) 7.2 (7.3)
Refinement
Resolution (A˚) 41.3–2.0 (2.07–2.00) 42.1–2.35 (2.43–2.35)
Number of unique
reflections
55105 17421
Rwork/Rfree (%) 20.8/26.0 22.9/29.2
Number of atoms
Protein 6160 2938
Water 159 17
Mean B factor (A˚2) 47.7 55.6
Rms deviation from ideal geometry
Bond length (A˚) 0.011 0.016
Bond angle () 1.332 1.466
PDB accession code 2OQ0 3B6Y
Values in parentheses are for the highest resolution shell.
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IFI16 Interaction with p53highlighting important functional differences between the two
HIN domains. Furthermore, the two HIN domains of IFI16 may
work cooperatively to stimulate the transcriptional activity of
p53. Together, our structures provide a molecular description
of the conserved HIN domain in this family, and offer insight
into the mechanism by which IFI16 recognizes, binds, and
potentially regulates p53.
RESULTS AND DISCUSSION
Overall Structures of IFI16 HIN-A and HIN-B Domains
The crystallized proteins of the first (HIN-A) and second (HIN-B)
IFI16 HIN domains span residues 192–393 and 515–710, respec-
tively. Data collection and refinement statistics are summarized
in Table 1. As shown in Figure 1B, each HIN domain adopts an
overall a/b fold that is further organized as two subdomains
oriented in tandem. The first subdomain (residues 199–281 in
HIN-A; residues 520–597 in HIN-B) is composed of eight
b strands and one a helix, forming a globular barrel with the
approximate dimensions 13 3 18 3 36 A˚3 for HIN-A and 14 3
18 3 35 A˚3 for HIN-B. Correspondingly, the second subdomain
(residues 314–389 in HIN-A; residues 628–705 in HIN-B) consists
of six b strands and one a helix, forming a second globular barrel
with the approximate dimensions 113 193 21 A˚3 for HIN-A and
103 203 22 A˚3 for HIN-B. In both cases the two subdomains are
connected by an extended interdomain linker (residues 282–313
in HIN-A; residues 598–627 in HIN-B) with two a helices in
between for HIN-A, and three a helices for HIN-B.
Structural comparison of the individual IFI16 HIN-A or HIN-B
subdomain with known folds using the DALI algorithm (Holm
and Sander, 1993) revealed that each subdomain of HIN-A and
HIN-B has high homology to the oligonucleotide/oligosaccha-
ride binding (OB) fold found in many proteins (see Figure S1A
available online), including replication protein A (RPA) (Boch-
karev et al., 1997; Deng et al., 2007), single-stranded DNA-
binding protein (SSB) (Kerr et al., 2003), aspartyl-tRNA-synthe-
tase (AspRS) (Charron et al., 2003; Poterszman et al., 1994),
BRCA2 (Yang et al., 2002), and telomere-binding protein
a subunit (a-TEBP) (Classen et al., 2001; Theobald and Schultz,
2003; Buczek and Horvath, 2006), with Z-scores ranging from
7.1 to 11.3. This finding is consistent with prediction based on
comparative sequence analysis that HIN domain contains two
OB folds (Albrecht et al., 2005). A canonical OB fold consists
of two three-stranded antiparallel b sheets packed orthogonally,
forming a closed b-barrel in a 1-2-3-5-4-1 topology, in which the
b1 strand is shared by both sheets (Theobald et al., 2003).
Comparison of the IFI16 HIN subdomains with these well-char-
acterized OB folds reveals significant variability in the length
and arrangement of the b strands in forming the barrel, as well
as the L12 and L45 loops, which are known to be important for
recognizing and binding to oligonucleotide or peptide substrates
(Theobald et al., 2003). For example the L12 and L45 loops of
each HIN subdomain consist of less than five residues, whereas
for other proteins these corresponding loops, especially L45,
can be greater than 15 residues (e.g., AspRS, RPA70, a-TEBP).
In addition, helical turn variations in the a helix connecting
strands b3 and b4 are also observed among the HIN subdomains
and other OB-fold proteins. This a helix is present in all four HIN
subdomains and is another conserved feature of the OB-fold420 Structure 19, 418–429, March 9, 2011 ª2011 Elsevier Ltd All rightemplate. This helix packs against the open edge of the barrel
and may be essential for structural integrity of the fold (Theobald
et al., 2003; Kerr et al., 2003). In the case of SSB and a-TEBP, the
OB fold of these two proteins uses a distorted helical turn to
mimic the a helix and, thus, accomplish the same effect (Kerr
et al., 2003). In total, over 50 structural homologs of IFI16 HIN
subdomains were identified, reflecting the widespread occur-
rence of the OB fold. Surprisingly, when a DALI search was per-
formed using the complete HIN-A or HIN-B domain (rather than
the individual subdomain), the closestmatchwas the structure of
the DNA-bound form of RPA 70 kDa subunit (RPA70, PDB:
1JMC) (Bochkarev et al., 1997), which contains two consecutive
OB folds but is only weakly superimposable with root-mean-
square deviation (rmsd) of 5.8 A˚ (over 173 Ca atoms) and 5.6 A˚
(over 170 Ca atoms), respectively (Figure S1B). Such a large
deviation is primarily seen in the size and conformation of various
secondary structural elements and variable loops, as well as in
the interdomain linker, which could possibly influence the sub-
domain/subdomain orientation. In fact the interdomain linker
bridging the two OB folds of RPA70 is highly flexible and can
adopt different conformations in the absence of DNA. Moreover,
unlike the HIN domain of IFI16, the two OB folds of RPA70 do not
come close enough to interact with each other without DNA
(Bochkareva et al., 2001).
Despite a moderate sequence identity of 40% between the
HIN-A and HIN-B domains, their crystal structures can be super-
imposed readily with rmsd of 1.3 A˚ for all the main chain Ca
atoms (Figure S1C). However, differences between the HIN-Ats reserved
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Figure 2. Subdomain/Subdomain Interactions of IFI16 HIN Domains
Close-up view of residues involved in subdomain/subdomain interaction for IFI16 HIN-A (left) and HIN-B (right).
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IFI16 Interaction with p53and HIN-B domains are seen in various loop regions and the
orientation of nearby secondary structural elements. For
example the L12 loops in subdomain 1 and subdomain 2 have
maximal shifts of 8.1 and 3.1 A˚, respectively, when HIN-A and
HIN-B are superimposed. Other substantial differences between
HIN-A and HIN-B are observed in the conformations of the L45
and L3a loops in subdomain 2, with deviations of 2.0 and
2.9 A˚, respectively.Subdomain/Subdomain Interactions of IFI16 HIN
Domains
For each HIN domain of IFI16, there appears to be extensive
interactions at the interface between its two OB-fold subdo-
mains. First, recombinant proteins comprising only one of the
subdomains were insoluble (data not shown), suggesting that
both subdomains may be required to provide proper structural
stability for the HIN domain. Second, several key intramolecular
interactions are evident between residues from each subdomain
(Figure 2). The observation that various aromatic interactions, in
addition to other noncovalent contacts, are present at the sub-
domain/subdomain interface of each HIN domain may explain
why disrupting these interactions was detrimental to the overall
fold of the structure. Furthermore, these aromatic residues are
mostly conserved across the HIN-200 protein family, further sug-
gesting that they are likely the key components of the HIN
domain.
To further evaluate if the interface formed by the OB-fold sub-
domains is interaction specific and not an artifact of crystal
packing, the Protein Interfaces, Surfaces and Assemblies
service PISA at European Bioinformatics Institute (http://www.
ebi.ac.uk/msd-srv/prot_int/pistart.html) was utilized. As pre-
sented in Table 2, various interaction and thermodynamic
parameters associated with interface analysis were acquired
for HIN-A and HIN-B, and in comparison with that of other
consecutive OB fold-containing proteins RPA70 (DNA bound;
PDB: 1JMC; or unbound, PDB: 1FGU), a-TEBP (PDB: 2I0Q),
and BRCA2 (PDB: 1MIU). The DiG P value is a measure of inter-
face specificity. It indicates the probability of getting a smaller
than obtained solvation free-energy gain DiG upon interface
formation, if interface atoms were selected randomly from
a protein surface. A P value of 0.5 implies that the formed
interface is not unique, whereas P value >0.5 indicates that the
interface is less hydrophobic than it could be and is likely to beStructure 19,an artifact of crystal packing. Finally, P value <0.5 signifies that
the interface formed has surprising hydrophobicity, implying it
is interaction specific (Krissinel and Henrick, 2007). Comparing
these DiG P values, we can easily observe that the interface
formed by the tandem OB-fold subdomains of HIN-A (P value
0.179) or HIN-B (P value 0.232) is the most interaction specific.
Interestingly, unlike HIN-A or HIN-B, the interface formed by
the OB-fold subdomains of RPA70 or a-TEBP appears likely to
be the result of crystal packing because the DiG P value for
each was above 0.5. Taken together, this suggests that the
HIN domains of IFI16 may constitute a unique arrangement of
closely interacting tandem OB folds that are stabilized by an
extensive array of hydrogen bonding and aromatic interactions.p53 C Terminus Binds to IFI16 HIN-A Domain
The role of IFI16 in p53-mediated transcriptional activation and
apoptosis was first suggested based on its physical association
with p53. Johnstone et al. (2000) mapped the interaction of the C
terminus of p53 to a large region of IFI16 encompassing the first
HIN-A domain (residues 155–476), but not the region containing
the second HIN-B domain (residues 477–729). To evaluate
whether the HIN-A domain itself is sufficient for interacting with
p53, we performed a protein-protein interaction assay using re-
combinant His-tagged IFI16 HIN-A domain (residues 192–393)
with GST-p53 C terminus (residues 355–393), GST-p53 C
terminus with the tetramerization domain (residues 311–393),
or GST alone. A similar assay was also conducted using
His-tagged IFI16 HIN-B domain (residues 515–710). As shown
in Figure 3A, the HIN-A domain was able to bind both constructs
of p53 C terminus, indicating that residues outside of the struc-
tured HIN-A domain are not required for p53 interaction.
Secondary structural analyses on these regions (residues
155–191 and 394–476) indicate that they are primarily unstruc-
tured (data not shown) and, thus, are not likely to participate in
binding p53 C terminus, which also lacks secondary structural
features. Despite having a similar fold to HIN-A, the HIN-B
domain was not able to bind any of the p53 C terminus
constructs.
To determine the strength of the interaction, we next
measured quenching of the intrinsic tyrosine fluorescence of
HIN-A or HIN-B domain upon addition of the p53 C terminus
(residues 355–393), which does not possess any tyrosine
residue. HIN-A domain contains five tyrosine residues (Y218,418–429, March 9, 2011 ª2011 Elsevier Ltd All rights reserved 421
Table 2. Summary of PISA Analysis of OB-Fold Subdomain/Subdomain Interaction
Subdomain 1 Subdomain 2 Interface DiG DiG NHB NSB NDS
Nat Nres Nat Nres area (A˚
2) kcal/mol P Value
HIN-A: 2OQ0 65 20 53 11 567.4 8.8 0.179 4 4 0
HIN-B: 3B6Y 49 15 45 11 484.4 5.2 0.232 3 0 0
RPA70A: 1JMC 34 12 25 11 278.9 0.1 0.650 5 2 0
RPA70A: 1FGU 6 1 7 2 52.5 0.2 0.576 0 0 0
TEBP: 2I0Q 85 19 75 17 689.0 4.5 0.556 12 5 0
BRCA2: 1MIU 48 14 37 10 394.1 4.5 0.415 3 1 0
Nat, number of interfacing atoms in the corresponding subdomain; Nres, number of interfacing residues in the corresponding subdomain; NHB, number
of hydrogen bonds across the interface; NSB, number of salt bridges across the interface; NDS, number of disulfide bonds across the interface.
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IFI16 Interaction with p53Y246, Y267, Y317, Y324), two of which (Y218, Y267) are surface
exposed. Similarly, HIN-B domain contains five tyrosine residues
(Y535, Y579, Y589, Y648, Y649) with three being surface
exposed (Y535, Y589, Y649). Two of the three surface-exposed
tyrosine residues of HIN-B (Y535, Y589) are situated near the
same region on the first OB-fold subdomain as that of HIN-A.
As demonstrated by the titration curve (Figure 3B), p53 C
terminus binds IFI16 HIN-A domain with an apparent affinity of
Kd 20 mM. However, the same fragment of p53 C terminus
did not show saturated binding to the HIN-B domain (Kd >
200 mM). This result further supports our findings that HIN-A is
the binding site for the C terminus of p53, suggesting that distinct
features present in HIN-A may be essential for p53 recognition.IFI16 HIN-A Domain Enhances p53-DNA Complex
Formation
The C terminus of p53 (residues 355–393) has been implicated in
several important activities of p53, including autoregulation,
protein-protein interactions, and nonspecific DNA binding
(Hupp et al., 1992; Gu and Roeder, 1997; Anderson et al.,
1997; Brazda et al., 2000; Ayed et al., 2001; Liu et al., 2003;
Weinberg et al., 2004). It has been suggested that the binding
of IFI16 to p53 C terminus may be important for p53 binding to
DNA. This was initially shown by polyacrylamide electrophoretic
mobility shift assays (EMSAs) in which the nuclear lysates of
Mol-4 T cells, containing constitutively expressed IFI16 and
p53, could bind p53-consensus oligonucleotides, and that
binding was reduced in the presence of an IFI16 antibody
(Johnstone et al., 2000). However, it was not clear whether
IFI16 was associating with p53 directly.
Here,weperformedEMSAusingpurified recombinantproteins
of IFI16 HIN-A domain (residues 192–393) and p53 (residues 82–
393) to assess whether the direct interaction between the two
proteins can influence p53’s sequence-specific DNA-binding
function. This p53 variant contains the central core sequence-
specific DNA-binding domain, the tetramerization domain, and
the C-terminal regulatory domain. As shown in Figure 4A, addi-
tion of IFI16 HIN-A protein was able to augment p53 (residues
82–393)’s binding to its consensus double-stranded DNA
sequence50-GGACATGCCCGGGCATGTCC-30, formingastable
protein-DNA complex in a dose-dependent manner (compare
lane 6: 0 mM IFI16 to lane 10: 80 mM IFI16). Increasing amounts
of IFI16 HIN-A protein by itself on the other hand, did not show
any binding to the same DNA molecules (lanes 1–5).422 Structure 19, 418–429, March 9, 2011 ª2011 Elsevier Ltd All righWe also performed EMSA using agarose gel to determine
the effect of IFI16 HIN-A domain on p53 (residues 82–393)
binding to larger DNA molecules (474 base pairs [bp]) contain-
ing p53-consensus sequence (Figure 4B). In the absence of
HIN-A, binding of p53 to its DNA target was not evident at
low concentration (lane 2). However, in the presence of
increasing amounts of HIN-A, p53 was able to bind to the
probe, as indicated by the formation of retarded bands with
corresponding disappearance of free DNA (lanes 3–5). Notably,
a more slowly migrating band was also observed in lanes 4 and
5, indicative of higher molecular weight protein-DNA
complexes. Using agarose EMSA, we also showed that IFI16
HIN-B domain, which does not interact with p53 C terminus,
was not capable of activating p53 (residues 82–393)’s DNA-
binding activity (Figure 4B, lanes 6–9). These results are
consistent with previously reported data in which proteins
that bind to the C terminus of p53 have been shown to
promote stable formation of sequence-specific p53-consensus
DNA complexes in EMSA experiments (Hupp et al., 1995; An-
derson et al., 1997; Brazda et al., 2000; Sarkari et al., 2010).
Thus, IFI16 shows biochemical features of other C-terminal
p53-binding proteins and can influence p53’s DNA-binding
properties.p53-Binding Surface of IFI16 HIN-A Domain
Given the overall structural similarities of HIN-A and HIN-B
domains of IFI16, we investigated the structural features that
are unique to HIN-A domain and mediate interaction with p53
C terminus. Comparing the electrostatic potential surfaces
of the two HIN domains based on our crystal structures
(Figure 5A), we hypothesized that the interaction with the basic
C terminus of p53 may be mediated by an overt acidic/hydro-
phobic patch observed on the surface of HIN-A (formed by
residues Y218, T220, E222, Y267, E272, E381), but not HIN-B
domain of IFI16. This surface encompasses the two exposed
tyrosine residues that presumably gave rise to the changes in
fluorescence signal upon p53 binding (Figure 3B) and is in an
area of the OB fold commonly found to interact with binding
partners (Theobald et al., 2003). To further elucidate the molec-
ular basis of p53 binding to HIN-A, we performed mutagenesis
studies examining the roles of the aforementioned surface-
exposed residues in mediating p53 interaction and activation
(Figure 5B). Compared to activation of p53 (residues 82–393)
by wild-type HIN-A domain (lane 3), T220A, E381A, Y218A,ts reserved
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Figure 3. Interaction of p53 C Terminus with IFI16 HIN-A or HIN-B Domain
(A) An equimolar mixture of His-tagged IFI16 HIN-A or HIN-B domain and aGST fusion protein containing the indicated p53 construct wasmixedwith glutathione-
sepharose (L). After washing, protein was eluted with glutathione and visualized by western (E) using antibody against His-tag.
(B) Increasing amounts of p53 (355–393) were incubated with IFI16 HIN-A (open triangle) or HIN-B (filled circle) domain, and binding was quantified by changes in
tyrosine fluorescence. Tyrosine side chains are shown in red on the surface representation of HIN-A and HIN-B crystal structures.
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IFI16 Interaction with p53E272A, E222A single mutants (lanes 5–8) were less effective at
activation of p53, especially T220A and Y218A. On the other
hand, double mutants 222/272 (lane 9) and 218/267 (lane 10),
and triple mutant 222/272/381 (lane 11) all abrogated p53 acti-
vation completely, suggesting that these residues contribute to
the p53 C terminus-binding surface on HIN-A. Circular
dichroism measurements indicated that all the mutants were
folded and had levels of secondary structure similar to that of
wild-type IFI16 (data not shown). Together these six residues
form a cluster between strands b2 and b50 of subdomain 1
and loop L505 of subdomain 2, creating the likely p53 C
terminus-interacting surface.Structure 19,IFI16 HIN-B Domain Enhances p53-DNA Binding by
Associating with p53 Core Domain
Although HIN-B domain of IFI16 does not interact with p53 C
terminus, we turned our effort next to investigate if HIN-B domain
could influence instead p53 (residues 82–360) binding to
consensus DNA. Employing the polyacrylamide EMSA shown
in Figure 6A, increasing amounts (0–80 mM) of HIN-B protein
was observed to greatly enhance p53-DNA binding as well as
forming higher molecular weight protein-DNA complexes.
Next, we asked if HIN-B could associate with p53 (residues
82–360) directly using a protein-protein interaction assay. As
shown in Figure 6B, p53 (residues 82–360) can interact weakly418–429, March 9, 2011 ª2011 Elsevier Ltd All rights reserved 423
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Figure 4. EMSA of p53 (82–393) with p53-
Consensus DNA Sequence in the Presence of
IFI16 HIN-A Domain
(A) Polyacrylamide EMSA reactions without p53 (lanes
1–5) or with constant amount (20 mM) of p53 (lanes
6–10), in the presence of increasing protein concentration
(0, 10, 20, 40, 80 mM) of HIN-A.
(B) Agarose EMSA of constant amount (0.2 mM) of p53 in
the presence of increasing protein concentration (0, 0.07,
0.2, 0.33 mM) of HIN-A (lanes 2–5) or HIN-B (lanes 6–9).
Structure
IFI16 Interaction with p53with GST-tagged HIN-B, but not GST-tagged HIN-A or GST
alone. As presented above, IFI16 HIN-B domain does not
interact with the C terminus of p53 (residues 311–393)
(Figure 3A), nor does it bind significantly to the 474 bp DNA
containing p53-consensus sequence (Figure 4B). Therefore,
our data suggest that binding of IFI16 HIN-B domain to p53
may be mediated through the core domain (residues 82–310)
of p53, especially when it is already bound to DNA.Cooperative Effect of Full-Length IFI16 on p53-DNA
Binding
Having studied the effects of individual HIN-A and HIN-B
domains of IFI16 on p53 sequence-specific DNA binding, it is
tempting to ask if the presence of both HIN domains together
enhances the activity cooperatively. To address such a question,
we purified the 82 kDa full-length IFI16 (residues 1–729) and per-
formed EMSA analysis with p53 (residues 82–393). As seen in
Figure 6C, increasing amounts of full-length IFI16 were incu-
bated with a constant amount of p53 and p53-consensus DNA
probe. Notably, addition of lowest concentration (0.07 mM) of
full-length IFI16 was able to better enhance p53-DNA binding
(compare lane 3 of Figure 6C with lane 3 of Figure 4B). This
suggests that the presence of both HIN-A and HIN-B domains
in the full-length IFI16 protein may cooperatively elevate the
effect of individual HIN domains on p53 binding to its consensus
sequence. Although full-length IFI16 also possesses a conserved
PYRIN domain at its N terminus, this domain was shown by
Johnstone et al. (2000) not to interact with p53.IFI16 Enhances p53-Mediated Transcription Activity
We next examined whether this IFI16-mediated enhancement of
p53 sequence-specific DNA binding has an effect on p53 tran-
scriptional activation. We performed luciferase reporter assays
to examine the effect of IFI16 on p53-mediated p21 promoter
activation. p21 is a functionally important p53-target gene
involved in cell cycle control and transcriptional regulation.
H1299, a human nonsmall cell lung carcinoma cell line, is used
for this study because it is known not to express endogenous
p53. In addition we have observed that H1299 cells also did
not express endogenous IFI16 (Figure S2). The cells were
cotransfected with p53 and/or IFI16 (full-length, HIN-A or424 Structure 19, 418–429, March 9, 2011 ª2011 Elsevier Ltd All rights reservedHIN-B) together with a luciferase reporter gene
containing the 20 bp 50 response element of
p21. As shown in Figure 7, p53 alone, but not
IFI16 (full-length, HIN-A or HIN-B), increased
the relative luciferase signal by 8-fold. A greaterthan 15-fold dose-dependent increase in luciferase activity was
observed when increasing amounts of full-length IFI16 were
cotransfected with p53. Interestingly, when coexpressed with
p53, the HIN-A or HIN-B domain of IFI16 was sufficient to
promote p53-mediated luciferase activity in a dose-dependent
manner, comparable to that of the full-length IFI16. This finding
indicates that IFI16, via either HIN-A or HIN-B domain, is capable
of upregulating p53-mediated transactivation function.
Full-Length IFI16 Model with p53
IFI16 is involved in transcriptional regulation by modulating
protein-DNA and protein-protein interactions with transcription
factors such as p53. Using small-angle X-ray scattering
(SAXS), an averaged bead model/molecular envelope of the
full-length IFI16 protein was derived (Figure 8), with a putative
arrangement of its three folded domains, PYRIN (based on
homology modeling of PYRIN domain of MNDA, PDB: 2DBG),
HIN-A (PDB: 2OQ0), and HIN-B (PDB: 3B6Y) in the bead model.
The model adopts a zigzag, elongated overall shape, which is in
accordance with the noncompact conformation indicated by the
Kratky plot (Figure S3B) and the relatively large Rg value 56 ± 2 A˚
(Figure S3A). The cross section throughout the bead model is
approximately 30–50 A˚. In addition the volume of the averaged
bead model is 1.95 3 105 A˚3, which is in a good agreement
with the Porod volume 1.8 ± 0.2 3 105 A˚3, estimated directly
from the scattering profile. The three domains of IFI16 are
oriented relatively independent of each other. In this arrange-
ment, kinks also occur at the junctions between PYRIN/HIN-A
and HIN-A/HIN-B at the nonstructured linkers. This model of
full-length IFI16 is consistent with its potential function as a scaf-
fold for multiple protein-protein interactions including p53, in
which HIN-A and HIN-B domains of IFI16 interact with the C
terminus and core domain of p53, respectively. HIN-A may
relieve unproductive nonspecific DNA interactions of p53, or
otherwise guide the C terminus to facilitate sequence-specific
DNA binding by the core domain, whereas HIN-B is likely to
interact with DNA-bound core domain stabilizing the p53-DNA
complex.
Conclusion
IFI16 plays an important role in regulating cell proliferation and
transcription through different protein-protein interactions. We
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Figure 5. p53 C Terminus-Binding Surface of IFI16 HIN-A Domain
(A) Transparent electrostatic surface representation of IFI16 HIN-A (left) and HIN-B (right) crystal structures. White, red, and blue colors correspond to neutral,
negatively, and positively charged surfaces, respectively.
(B) Agarose EMSA of p53 (82–393) with wild-type or mutant IFI16 HIN-A (left). Molar ratio of p53 to HIN-A is 1:3. Surface representation of IFI16 HIN-A (right).
Residues involved in binding are colored in magenta.
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IFI16 Interaction with p53have solved the crystal structures of the HIN-A and HIN-B
domains of IFI16, representing the first experimentally deter-
mined HIN domain structures of the HIN-200 family. Despite
having low-sequence identity to the OB folds commonly found
in various proteins, both HIN domains of IFI16 possess tandem
OB folds joined by an a-helical interdomain linker. It is worth
noting that the majority of the OB-fold structures reported to
date in the Protein Data Bank (PDB) are solitary. Thus, IFI16 joins
mouse BRCA2 (PDB: 1MIU), Oxytricha nova a-TEBP (PDB:
2I0Q), and human RPA70 (PDB: 1JMC) to be the only proteins
with structural information showing consecutive OB folds. Struc-
tural analysis of the human RPA70 has revealed a similar domain
organization such that it has four domains (RPA70N, DBD-A,
DBD-B, DBD-C) each with an OB fold. The N-terminal OB fold
of RPA70 has a role in mediating protein-protein interaction
with p53 (Bochkareva et al., 2005), whereas the remaining three
OB folds all participate in single-stranded DNA binding
(Bochkarev et al., 1997, 2000, 2001). Although the HIN domain
of IFI16 constitutes a unique arrangement of tandem OB foldsStructure 19,with specific interdomain interactions, it is possible that the
four OB folds are also involved in a modular and concerted
fashion for multiple substrate recognition analogous to those of
RPA70.
The work presented here extends previous studies demon-
strating the association of IFI16 HIN-A domain with the C
terminus of p53 and further defines the mechanism by which
IFI16 stimulates p53-mediated transcriptional activation.
Although HIN-A and HIN-B domains of IFI16 are structurally
similar and both modulate p53 sequence-specific DNA binding,
they interact with p53 differently. IFI16 recognizes the basic p53
C terminus through an acidic/hydrophobic surface present on
and unique to HIN-A domain, whereas HIN-B domain associates
instead with core domain of p53. It is likely that HIN-A domain
prevents p53 from nonspecific DNA interaction via its C
terminus, whereas HIN-B domain stabilizes p53-DNA binding.
Given its putative role as a scaffold molecule, full-length IFI16
is also likely involved in recruitment of additional factors to the
p53-binding sites via its PYRIN domain. Indeed, the BRCA1418–429, March 9, 2011 ª2011 Elsevier Ltd All rights reserved 425
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Figure 6. IFI16 HIN-B Domain Enhances
p53-DNA Binding by Associating with p53
Core Domain
(A) Polyacrylamide EMSA reactions without p53
(82–360) (lanes 1–5) or with constant amount
(2 mM) of p53 (lanes 6–10), in the presence of
increasing protein concentration (0, 10, 20, 40,
80 mM) of HIN-B.
(B) GST-pull-down of p53 and HIN-B domain. An
equimolar mixture of His-tagged p53 (82–360)
and GST-tagged IFI16 HIN-B, GST-tagged IFI16
HIN-A, or GST protein alone was mixed with gluta-
thione-sepharose (L). After washing (Washes 1–3),
protein was eluted (E1, E2) with reduced gluta-
thione and visualized by Coomassie blue staining.
(C) Agarose EMSA of constant amount (0.2 mM)
ofp53 (82–393) in thepresenceof increasingprotein
concentration (0, 0.07, 0.2 mM) of full-length IFI16.
Structure
IFI16 Interaction with p53tumor suppressor protein is known to interact with IFI16 PYRIN
domain and promote p53-dependent apoptosis (Aglipay et al.,
2003). Interestingly, we and others have shown that p53 can
also associate directly with BRCA1 (Zhang et al., 1998; Mark
et al., 2005), thus suggesting intricate crosstalk among the three
proteins and also adding another level of complexity in the func-
tion and regulation of IFI16.
EXPERIMENTAL PROCEDURES
Expression and Purification
IFI16 gene fragments coding for HIN-A domain (residues 192–393) and HIN-
B domain (515–710) were amplified from human IFI16 cDNA (Mammalian
Gene Collection, Structural Genomic Consortium) by PCR and subcloned
into pET15b (Novagen) expression vector. Both IFI16 domains HIN-A and
HIN-B proteins were expressed in E. coli BL21-CondonPlus cells (Strata-
gene) with N-terminal His6-tag in selenomethionine (Se-Met)-containing
media. Protein purification was performed by Co2+ affinity column (TALON).426 Structure 19, 418–429, March 9, 2011 ª2011 Elsevier Ltd All rights reservedRecombinant human p53 protein (residues 355–
393, 311–393, 82–360, 82–393) was subcloned
into pET15b (Novagen) or pGEX-2TK (Amer-
sham) vector and expressed in and purified
from E. coli BL21-pLysS cells (Stratagene) as
previously described (Ayed et al., 2001; Mark
et al., 2005).
Crystallization, Data Collection, and
Structure Determination of IFI16 HIN-A
Crystals of the Se-Met-labeled IFI16 HIN-A
(35 mg/ml) were obtained by the sitting drop vapor
diffusion method by mixing the protein with an
equal volume of reservoir solution containing
26% PEG 6000, 0.2 M MgCl2, and 0.1 M Tris-
HCl at pH 8.5. The crystals belong to the mono-
clinic space group P21 with unit cell parameters
of a = 43.3 A˚, b = 88.9 A˚, c = 112.8 A˚, and b =
99.4. For data collection and structure determi-
nation details, please refer to Supplemental
Experimental Procedures.
Crystallization, Data Collection, and
Structure Determination of IFI16 HIN-B
Native crystals of IFI16 HIN-B (23 mg/ml) were
obtained by the sitting drop vapor diffusionmethod by mixing the protein with an equal volume of reservoir solution
containing 26% PEG 4000, 0.2 M NH4SO4, and 0.1 M sodium cacodylate
buffer at pH 6.5. The crystals belong to the orthorhombic space group
P212121 with unit cell parameters of a = 43.0 A˚, b = 92.9 A˚, and c =
100.3 A˚ with two molecules in the asymmetric unit. For data collection
and structure determination details, please refer to Supplemental Experi-
mental Procedures.
Protein-Protein Interaction Assays
Purified GST, GST-p53 (residues 355–393), or GST-p53 (residues 311–393)
fusion protein was first mixed with His-tagged IFI16 (residues 192–393) or
His-tagged IFI16 (residues 515–710) protein in assay buffer (20 mM HEPES
[pH 7.6], 150 mM NaCl) and then incubated with the glutathione beads (Amer-
sham) at 4C for 2 hr. After extensive washing with assay buffer, bound
proteins were eluted with 30 mM reduced glutathione and detected after
SDS-PAGE by western analysis using antibody against His-tag (QIAGEN).
Similar assays were conducted for purified GST, GST-HIN-A (residues
192–393), or GST-HIN-B (residues 515–710) fusion protein with His-tagged
p53 protein (residues 82–360).
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Figure 7. IFI16 Enhances p53-Mediated Transcription of the p21
Promoter
H1299 cells were cotransfected with the luciferase reporter vector containing
the full-length p21 promoter, p21-Luc, and with pcDNA3-p53 and/or pcDNA3-
IFI116 (full-length [FL], HIN-A or HIN-B). The cells were lysed and assayed for
luciferase activity 48 hr after transfection. Standard error was calculated using
three independent experimental readings. See also Figure S2.
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Figure 8. Model of Full-Length IFI16
An averaged bead model/molecular envelope of the full-length IFI16
calculated from SAXS data, with dimension measurements and putative
arrangement of its three folded domains: PYRIN, HIN-A, and HIN-B. See
also Figure S3.
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IFI16 Interaction with p53Intrinsic Tyrosine Fluorescence Assay
Direct binding of p53 C terminus (residues 355–393) to IFI16 HIN-A domain
(residues 192–393) or HIN-B domain (residues 515–710) was characterized
based on principles employed by Leclerc et al. (1993), Gupta et al. (2008),
and Yan et al. (2008). A p53-binding titration was performed manually by mix-
ing a solution of IFI16 protein (final concentration 1 mM) with increasing
amounts of p53 (0–250 mM) in a buffer containing 25 mM Tris-HCl (pH 8.0)
and 75 mM NaCl in a total volume of 150 ml at room temperature. After mixing,
the intrinsic tyrosine fluorescence intensity (I) was measured using a time-
based experimental module, which averages the fluorescence intensity from
30 readings with each reading for 1 s and sets the excitation wavelength at
278 nm, emission wavelength at 307 nm, and bandwidth at 4 nm. The
quenched fluorescence (Iq) was calculated by IoI, in which Io was the fluores-
cence intensity of IFI16 protein without p53. Background signals from the
buffer and ligand were corrected. The dissociation constants (Kd) were deter-
mined by fitting the binding curve to Equation 1, using KaleidaGraph Version
3.0 (Abelbeck Software):
Iq = Io +
ðIN  IoÞð1+ ½P=kd + ½L=kdÞ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1+ ½P=kd + ½L=kdÞ24½P½Lð1=kdÞ2
q
½Lð2=kdÞ ;
(1)
where Iq is the fluorescence intensity at a given total concentration of target
ligand, [L]. [P] is the total concentration of protein in the reaction. Kd is the
dissociation constant. IN is the fluorescence intensity at saturation, and Io is
the fluorescence intensity in the absence of ligand.
Polyacrylamide EMSA
p53 (2–20 mM) was incubated with double-stranded DNA probe 50-
GGACATGCCCGGGCATGTCC-30 (1–2 pmol) tagged with the monoreactive
fluorescent reagent Cy5-Dye (Sigma) in EMSA buffer (20 mM Tris-HCl [pH
6.8], 150 mM NaCl, 10% [v/v] glycerol, 5 mM DTT) in the presence of IFI16
HIN-A or HIN-B protein (at final concentrations of 0–80 mM). Complexes
were resolved by electrophoresis at 100 V at room temperature using a pre-
run 5% polyacrylamide gel containing Tris-Borate-EDTA buffer and then visu-
alized by red fluorescence emission measured at 635 nm using a STORM860
scanner (Molecular Dynamics).Structure 19,Agarose EMSA
DNA (600 ng of PvuII fragments of pPGM2) (Brazda et al., 2006; Jagelska et al.,
2008), p53, and IFI16 were mixed at various ratios in 20 ml of the DNA-binding
buffer (5 mM Tris-HCl [pH 7.0], 1 mM EDTA, 50 mM KCl, and 0.01% Triton
X-100). The samples were incubated for 10 min at 4C and loaded onto
a 1% agarose gel (SERVA) containing 0.333 Tris-Borate-EDTA buffer.
Agarose electrophoresis was performed for 4 hr at 100 V at 4C. The gels
were stained with ethidium bromide and photographed.
Cell Culture and Luciferase Assay
Human nonsmall cell lung carcinoma cell line H1299 was obtained from the
Benchimol laboratory and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). pcDNA3-p53 and
the luciferase reporter construct carrying the p21 promoter (p21-Luc) were
also obtained from the Benchimol laboratory. An amplified fragment of full-
length IFI16, HIN-A, or HIN-B from human IFI16 cDNA (Mammalian Gene
Collection, Structural Genomic Consortium) was subcloned into pcDNA3
(Invitrogen). H1299 cells at80%confluence in a 6-well plate were transfected
using Lipofectamine 2000 (Invitrogen). At 48 hr after transfection, luciferase
assay was performed using the Luciferase Assay Kit (Promega) and measured
using the SpectraMax M5 luminometer (Molecular Devices). Standard error
was calculated using three independent experimental readings.
SAXS Experiments, Data Analysis, and Bead Model Reconstruction
Both SAX and wide-angle X-ray scattering (WAXS) were performed at beam-
line 12-ID of the Advanced Photon Sources (APS) at the Argonne National
Laboratory. A detailed description about experimental procedure, processing
and analysis of scattering data, and bead model reconstruction can be found
in Supplemental Experimental Procedures.ACCESSION NUMBERS
Atomic coordinates and structure factors for the reported crystal structures
have been deposited in the PDB under the accession codes 2OQ0 and 3B6Y.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at doi:10.1016/j.
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